A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Summary

This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients

Timeline

Start

2009-10

Primary completion

2014-07

Completion

2016-01

Outcome

Missed primary endpoint

registry Hazard Ratio (HR) 1.357 (95% CI 0.802 to 2.296) NCT00987935 ↗

Drugs

Indications